We recently published a list of 10 Firms Lead Rally on Impressive Q1 Earnings, Optimistic Outlooks. In this article, we are ...

Hims & Hers Health (NYSE:HIMS) recently announced a partnership with Novo Nordisk to enhance obesity care access in the U.S., coinciding with a notable 24% increase in its stock price over the last ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

SHOPPING: PSD underwear takes your style to the next level. Bold designs and unmatched comfort for a statement that starts ...

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...

Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Drugmaker Novo Nordisk announced Tuesday that Wegovy will be available through telehealth providers. The providers -- Hims & ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...